Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$83.96M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$84.00M
Gross Margin
-736.46%
TTM Avg
-368.23%
3Y Avg
-290.99%
5Y Avg
-1574.61%
Market Cap
$84.70M
Gross Margin
82.44%
TTM Avg
83.07%
3Y Avg
-40.55%
5Y Avg
-241.44%
Market Cap
$84.75M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$81.22M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$79.46M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$87.86M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | $83.49M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -736.46% | -368.23% | -290.99% | -1574.61% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | 82.44% | 83.07% | -40.55% | -241.44% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | 0.00% | 0.00% | 0.00% | 0.00% |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 46.51% | 45.81% | 42.58% | 41.06% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | 100.00% | 100.00% | 100.00% | 100.00% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | 100.00% | 100.00% | 100.00% | 100.00% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 40.32% | 35.69% | 34.43% | 37.90% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
